The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00240279
First received: October 16, 2005
Last updated: November 18, 2010
Last verified: November 2010

October 16, 2005
November 18, 2010
January 2003
October 2008   (final data collection date for primary outcome measure)
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
Same as current
Complete list of historical versions of study NCT00240279 on ClinicalTrials.gov Archive Site
To investigate the effect of rosuvastatin compared to placebo on the aortic pressure wave in hemodialysis patients (at 3 months/ 6 months and 12 months).
Same as current
Not Provided
Not Provided
 
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Hypercholesterolemia
  • Drug: Rosuvastatin
  • Procedure: aortic pulse wave velocity measurements
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent, between 50 and 80 years of age, end stage renal failure patients receiving hemodialysis

Exclusion Criteria:

  • Received statins within past 6 months, a clear indication for use of lipid altering drug, contra indication for lipid altering drug, history of statin induced myopathy items in very
Both
50 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00240279
4522IL/0096 Dutch SubStudy, D3562C00096
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: AstraZeneca Crestor Medical Sciences Director, MD AstraZeneca
AstraZeneca
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP